Related Experiment Video
Updated: Aug 8, 2026

A Proinflammatory, Degenerative Organ Culture Model to Simulate Early-Stage Intervertebral Disc Disease.
Published on: February 14, 2021
Up-regulation of niacinamide in intervertebral disc aggrecan in vitro
Xiaoqian Xiong1, Shuhua Yang, Zengwu Shao
1Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Insights
Niacinamide (Nia) shows potential in treating intervertebral disc (IVD) degeneration. This study found Nia increased aggrecan expression and protected IVDs from damage in vitro, suggesting a possible clinical therapy.
Area of Science:
- Biochemistry
- Cell Biology
- Regenerative Medicine
Background:
- Intervertebral disc (IVD) degeneration is a significant cause of back pain.
- Interleukin-1 (IL-1) is a key mediator in IVD degeneration.
- Aggrecan is a crucial proteoglycan for IVD structure and function.
Purpose of the Study:
- To investigate the regulatory effects of niacinamide (Nia) on IVD aggrecan expression in vitro.
- To evaluate Nia's protective effects against IL-1-induced IVD degeneration.
Main Methods:
- Established a rabbit IVD degeneration model induced by IL-1.
- Treated normal and degenerated IVDs with varying concentrations of Nia (0.05, 0.25, 0.5 mg/mL).
- Assessed glycosaminoglycan (GS) content, safranin O-fast green staining intensity, and aggrecan core protein gene expression via RT-PCR.
Main Results:
- Nia treatment significantly increased GS content in nucleus pulposus (NP) and fibrous rings, with dose-dependent effects.
- Safranin O-fast green staining indicated increased matrix density and alleviated histological damage in Nia-treated IVDs.
- RT-PCR confirmed that Nia upregulated aggrecan core protein gene expression in IL-1-induced degenerated IVDs.
Conclusions:
- Niacinamide upregulates aggrecan expression in intervertebral discs.
- Nia demonstrates protective effects against IL-1-induced IVD degeneration in vitro.
- Nia represents a potential therapeutic agent for clinical management of IVD degeneration.
Abstract:
The regulatory effects of niacinamide (Nia) on intervertebral disc (IVD) aggrecan in vitro was investigated. Chiba's 10 ng/mL interleukin-1 (IL-1)-induced rabbit IVD degeneration model in vitro was established. 0.5, 0.25 and 0.05 mg/mL Nia was added to normal and degenerated IVDs for intervention. On the first and second week after intervention, safranin O-fast green staining intensity and glycosaminoglycan (GS) content were measured. The expression of aggrecan core protein was detected by RT-PCR. The results showed: (1) After treatment with 0.5 mg/mL Nia for one week, the GS content in nucleus pulposus (NP) was increased by 44.8% as compared with control group (P < 0 01); The GS content in IL-1 induction groups was increased with the increase of Nia concentrations: After treatment with 0.5 mg/mL for one week, the GS content in NP was increased by 68.3% as compared with control group (P < 0.01). After two weeks, GS content in NP and fibrous rings was still higher than in control group at the same period (P < 0.01) and untreated group (P < 0.01). (2) Safranin O-fast green staining revealed that with the increase of Nia concentrations, staining density in NP and fibrous rings was increased and histological structure damage to IVDs by IL-1beta was alleviated. (3) RT-PCR showed that the expression of core protein gene in IL-1beta-induced degenerated IVDS was increased with the increase of Nia concentrations. It was concluded that under conditions in vitro, Nia could up-regulate the expression of aggrecan in IVDs and protect IVDs from IL-1beta-induced degeneration at least partially, which offers a potential choice for IVD degeneration clinical therapy.
Related Concept Videos
Degenerative Disc Disease I: Introduction
Degenerative Disc Disease ll: Pathophysiology
Herniated Intervertebral Disc l: Introduction
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
